All Cured of Hep C Genotype 2 or 3 in Arm of PSI-7977 Trial
Share
Follow Us
Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3
— 24 out of 24 subjects with HCV genotype 2 or 3 achieved an SVR after 12 weeks of treatment with PSI-7977 400mg QD and pegylated interferon and ribavirin
— SVR12 results from PROTON in HCV genotype 1 subjects are expected in second half of 2011
PRINCETON, N.J., July 20, 2011 /PRNewswire/ — Pharmasset, Inc. (Nasdaq: VRUS) announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously. Twenty four out of twenty four subjects (100%) who completed treatment achieved an SVR, defined as HCV RNA below the limit of detection (<15 IU/ml) 24 weeks after the completion of treatment. No subject exhibited breakthrough on treatment or relapse after treatment.
Continue reading this entire article:
http://www.prnewswire.com/news-releases/pharmasset-announces-final-svr-data-from-proton-trial-with-psi-7977-in-subjects-infected-with-hepatitis-c-infection-genotype-2-or-3-125877113.html
